Значения термина strontium ranelate на английском

In general, strontium ranelate therapy did not seem to be associated with an increased risk of adverse events.

Treatment with strontium ranelate was calculated against a no-treatment option to evaluate whether it could be given cost-effectively.

An incremental analysis against alendronate was also conducted to estimate the cost-effectiveness of strontium ranelate relative to a current standard treatment.

From the algorithm used, it is seen that strontium ranelate can be used cost-effectively in women at relatively high risk of osteoporotic fracture.

Some nervous system disorders, including mental impairment, disturbed consciousness, memory loss and seizures, were also more common in patients randomised to strontium ranelate.

If it were believed that the efficacy of strontium ranelate is dependent on either age or absolute risk, this would need to be proven.

Conclusions: Strontium ranelate was shown to be clinically effective in the prevention of osteoporotic fractures.

Strontium ranelate provided gains in QALYs compared with no treatment in women with sufficient calcium and vitamin D intakes.